VTAK Quote, Financials, Valuation and Earnings

InfuSystems Holdings has a net margin of -4291.67% compared to Catheter Precision's net margin of 5.12%. Catheter Precision's return on equity of -65.84% beat InfuSystems Holdings's return on equity of 2.8%.

Catheter Precision has a consensus price target of --, signalling upside risk potential of 429.24%. On the other hand InfuSystems Holdings has an analysts' consensus of -- which suggests that it could grow by 72.05%. Given that Catheter Precision has higher upside potential than InfuSystems Holdings, analysts believe Catheter Precision is more attractive than InfuSystems Holdings.

Catheter Precision has a beta of -0.210, which suggesting that the stock is 121.025% less volatile than S&P 500. In comparison InfuSystems Holdings has a beta of 1.528, suggesting its more volatile than the S&P 500 by 52.819%.

Catheter Precision has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystems Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision pays -- of its earnings as a dividend. InfuSystems Holdings pays out -- of its earnings as a dividend.

Catheter Precision quarterly revenues are $96K, which are smaller than InfuSystems Holdings quarterly revenues of $35.3M. Catheter Precision's net income of -$4.1M is lower than InfuSystems Holdings's net income of $1.8M. Notably, Catheter Precision's price-to-earnings ratio is 0.43x while InfuSystems Holdings's PE ratio is 129.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision is 1.01x versus 1.33x for InfuSystems Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics has a net margin of -4291.67% compared to Catheter Precision's net margin of --. Catheter Precision's return on equity of -65.84% beat Plus Therapeutics's return on equity of --.

Catheter Precision has a consensus price target of --, signalling upside risk potential of 429.24%. On the other hand Plus Therapeutics has an analysts' consensus of -- which suggests that it could grow by 1358.33%. Given that Plus Therapeutics has higher upside potential than Catheter Precision, analysts believe Plus Therapeutics is more attractive than Catheter Precision.

Catheter Precision has a beta of -0.210, which suggesting that the stock is 121.025% less volatile than S&P 500. In comparison Plus Therapeutics has a beta of 0.705, suggesting its less volatile than the S&P 500 by 29.519%.

Catheter Precision has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision pays -- of its earnings as a dividend. Plus Therapeutics pays out -- of its earnings as a dividend.

Catheter Precision quarterly revenues are $96K, which are larger than Plus Therapeutics quarterly revenues of --. Catheter Precision's net income of -$4.1M is lower than Plus Therapeutics's net income of -$2.9M. Notably, Catheter Precision's price-to-earnings ratio is 0.43x while Plus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision is 1.01x versus 1.18x for Plus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -4291.67% compared to Catheter Precision's net margin of -18.58%. Catheter Precision's return on equity of -65.84% beat Retractable Technologies's return on equity of -16.83%.

Catheter Precision has a consensus price target of --, signalling upside risk potential of 429.24%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Catheter Precision has higher upside potential than Retractable Technologies, analysts believe Catheter Precision is more attractive than Retractable Technologies.

Catheter Precision has a beta of -0.210, which suggesting that the stock is 121.025% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.979, suggesting its more volatile than the S&P 500 by 97.877%.

Catheter Precision has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision pays -- of its earnings as a dividend. Retractable Technologies pays out -3.32% of its earnings as a dividend.

Catheter Precision quarterly revenues are $96K, which are smaller than Retractable Technologies quarterly revenues of $10.3M. Catheter Precision's net income of -$4.1M is lower than Retractable Technologies's net income of -$1.9M. Notably, Catheter Precision's price-to-earnings ratio is 0.43x while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision is 1.01x versus 0.50x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -4291.67% compared to Catheter Precision's net margin of -17.98%. Catheter Precision's return on equity of -65.84% beat Xtant Medical Holdings's return on equity of -35.98%.

Catheter Precision has a consensus price target of --, signalling upside risk potential of 429.24%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 469.04%. Given that Xtant Medical Holdings has higher upside potential than Catheter Precision, analysts believe Xtant Medical Holdings is more attractive than Catheter Precision.

Catheter Precision has a beta of -0.210, which suggesting that the stock is 121.025% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

Catheter Precision has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Catheter Precision quarterly revenues are $96K, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. Catheter Precision's net income of -$4.1M is higher than Xtant Medical Holdings's net income of -$5M. Notably, Catheter Precision's price-to-earnings ratio is 0.43x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision is 1.01x versus 0.46x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.